Co.Protect 360

The most trusted supplier of branded PPE for sports leagues, companies & communities

The first and only FDA EUA single use molecular test available over-the-counter.

Here's how our employer program works:

Test at home. Get back to work with LUCI PASS.

Employees test at home

Lucira Check It is

Accurate: Performance equal to best-in-class molecular assays run in high complexity labs

Easy to Use: In Usability and Clinical trials submitted to FDA: 100% of users successfully able to perform test

Results in 30 minutes or less:

Positive results display in as few as 11 minutes; negative
results confirmed in 30 minutes

Get back to work with LUCI PASS

We created the LUCI PASS™ to make it easy for you to receive a free, verified Lucira test result. After taking our test, you simply text to access our secure LUCI portal, and then follow a few steps to submit your results.

You will receive a free LUCI PASS with your verified test results back on your phone. No app is required. LUCI can also transmit results to relevant public health authorities.

LUCI was developed to support our over-the-counter test kit.

Lucira’s Clinical Performance

PCR quality molecular accuracy in 30 minutes or less

Lucira’s Clinical Performance PCR quality molecular accuracy in 30 minutes or less
In two Community Testing Studies which included individuals with and without COVID-19 symptoms, the Lucira test was compared to the Hologic Panther Fusion, one of the highest sensitivity FDA authorized SARS-CoV-2 PCR tests. Lucira achieved 98% accuracy(1), excluding samples with very low levels of virus that possibly no longer reflected active infection(4). Across all data, Lucira achieved 96% accuracy(3).

  • Authorized for self-collection for individuals aged 14+ and adult collection for children aged 2-13
  • Able to detect the emerging spike double mutant, Southern California, UK, South African and Brazilian COVID-19 strains

Case Studies

"We've been using Lucira Check It to keep our film crews rolling and it's quickly become our go to test.

Best of all, our crew can either test at home or on site, and all they have to do is get their LUCI PASS to be

here on set. I wish we'd had this test a year ago! It's all the buzz in our studio."

- Los Angeles Producer


"Being able to meet in small groups in person has been a total game changer for our team.

I don't think any of us realized how much we missed working together in the same room.

We're expanding our Lucira program to a broader group of employees."

- Bay Area Biotech Executive



Why trust molecular

Both molecular and antigen tests are designed to detect whether or not someone has an active COVID-19 infection. However, the way they work is different.

Molecular tests have higher sensitivity and can detect when SARS-CoV-2 is present in a sample at significantly lower viral levels versus antigen tests.

Molecular tests, such as PCR and Lucira's test, copy the virus's genetic material and amplify the virus's genetical material as the test is running.

This allows molecular tests to detect whether SARS-CoV-2 is present at much lower viral levels.

Antigen tests do not copy or amplify the viral target and require higher levels of starting virus to produce a

positive result. Molecular tests are considered diagnostically definitive and do not require confirmatory testing.

They are able to detect SARS-CoV-2 virus across a broader range of viral loads, making them more

sensitive and reliable.

This home test kit has not been FDA cleared or approved. This home test kit has been authorized by FDA under EUA. This home test kit has been authorized only for the testing of nasal swabs for detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This home test kit is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or revoked sooner.

1. Excluding samples with very low levels of virus (>37.5 Ct), Lucira Community Testing Study 07A-CLI 006 Fall 2020 and Lucira Community Testing Study 07A-CLI 007 Winter 2021 (n=394) 2. Lucira Usability Clinical Study 07A-CLI-004/005 conducted Summer 2020 (n=352) 3. Lucira Community Testing Study 07A-CLI 006 Fall 2020 and Lucira Community Testing Study 07A-CLI 007 Winter 2021 (n=404)Text